Related Experiment Video
Updated: Apr 17, 2026
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
Published on: October 10, 2025
Improving outcomes for neurofibromatosis 1-associated brain tumors
Nicole M Brossier1, David H Gutmann
1Department of Pediatrics, St. Louis Children's Hospital, St. Louis, MO, USA.
Abstract:
Children and adults with neurofibromatosis type 1 (NF1) are predisposed to developing CNS tumors, including optic pathway gliomas (OPGs), brainstem gliomas (BSGs) and high-grade gliomas. Although current first-line treatments for low-grade gliomas (OPGs and BSGs) may prevent further tumor growth, they rarely result in restoration of the associated visual or neurological deficits. The availability of accurate small-animal models of NF1-associated brain tumors has established tractable experimental platforms for the discovery and evaluation of promising therapeutic agents. On the basis of these preclinical studies, biologically targeted agents are now being evaluated in children with NF1-associated low-grade brain tumors. Collectively, these models have also begun to reveal potential neuroprotective and risk assessment strategies for this brain tumor-prone population.
Insights
Neurofibromatosis type 1 (NF1) patients develop brain tumors like optic pathway gliomas. Animal models aid testing new targeted therapies and neuroprotective strategies for NF1 brain tumors.
Area of Science:
- Oncology
- Genetics
- Neurology
Background:
- Neurofibromatosis type 1 (NF1) predisposes individuals to central nervous system (CNS) tumors, including optic pathway gliomas (OPGs) and brainstem gliomas (BSGs).
- Current treatments for low-grade NF1-associated gliomas often halt progression but seldom reverse existing visual or neurological deficits.
Purpose of the Study:
- To review the development and application of small-animal models for NF1-associated brain tumors.
- To discuss the translation of preclinical findings into clinical trials for targeted therapies in pediatric NF1 patients.
- To explore the potential of these models in identifying neuroprotective and risk assessment strategies.
Main Methods:
- Utilizing established small-animal models that accurately recapitulate NF1-associated brain tumors.
- Evaluating biologically targeted agents in preclinical settings.
- Translating promising preclinical results into clinical evaluations in children with NF1.
Main Results:
- Small-animal models provide effective platforms for discovering and testing novel therapeutic agents for NF1 brain tumors.
- Biologically targeted agents, informed by preclinical data, are now under investigation in human clinical trials.
- These models are contributing to the understanding of neuroprotection and risk assessment in NF1.
Conclusions:
- Preclinical models are crucial for advancing the treatment of NF1-associated brain tumors.
- Targeted therapies show promise for improving outcomes in NF1 patients.
- Future research directions include neuroprotection and improved risk stratification for NF1-related CNS malignancies.
